Document Detail

Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration.
MedLine Citation:
PMID:  9056049     Owner:  NLM     Status:  MEDLINE    
AIMS: The purpose of this study was to investigate the effect of activated charcoal on the absorption of amlodipine, with special reference to delayed charcoal administration. METHODS: Thirty-two healthy volunteers, eight subjects in four parallel groups, ingested 10 mg of amlodipine on an empty stomach. Activated charcoal (25 g in 300 ml of water) was ingested either immediately afterwards or 2 h or 6 h after amlodipine, or amlodipine was ingested with 300 ml of water only (control). Plasma concentrations and the cumulative excretion of amlodipine into urine were measured by GC-MS for 96 h and 72 h, respectively. In addition, adsorption of amlodipine to charcoal was studied in vitro. RESULTS: Activated charcoal administered immediately after amlodipine reduced the amlodipine AUC(0.96 h) and the 72-h urinary excretion by 99% (P < 0.0005). After a delay of 2 h in charcoal administration the AUC(0.96 h) was reduced by 49% (P = 0.001), but after a delay of 6 h the reduction was 15% only (P = NS). At a charcoal:drug ratio of 5:1, about 90% of amlodipine was adsorbed by charcoal in vitro; at ratios of 10:1 and 20:1, adsorption was practically complete. CONCLUSIONS: Activated charcoal almost completely prevented amlodipine absorption when administered immediately after amlodipine ingestion. Charcoal also markedly reduced amlodipine absorption when given 2 h after amlodipine; in amlodipine overdose, administration of charcoal may be beneficial even later. We conclude that administration of activated charcoal is the method of choice to prevent absorption of amlodipine in amlodipine overdose.
K Laine; K T Kivistö; I Laakso; P J Neuvonen
Related Documents :
21932609 - Small nuclear ribonucleoprotein polypeptide n quantitative methylation analysis in infa...
21476999 - Consequences of the term breech trial in denmark.
21284459 - Analysis of the risk of shunt failure or infection related to cerebrospinal fluid cell ...
17486199 - Results of a program for the prevention of blindness caused by retinopathy of prematuri...
21514859 - Neurological examination of late-preterm infants at term age.
12269179 - Malthus on long swings: the general case.
3723559 - Is reserpine a human teratogen?
6684889 - Indochinese refugee fertility rates and pregnancy risk factors, oregon.
14524629 - Congenital nutritional muscular dystrophy in a beef calf.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  British journal of clinical pharmacology     Volume:  43     ISSN:  0306-5251     ISO Abbreviation:  Br J Clin Pharmacol     Publication Date:  1997 Jan 
Date Detail:
Created Date:  1997-05-29     Completed Date:  1997-05-29     Revised Date:  2009-10-02    
Medline Journal Info:
Nlm Unique ID:  7503323     Medline TA:  Br J Clin Pharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  29-33     Citation Subset:  IM    
Department of Pharmacology and Clinical Pharmacology, University of Turku, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adsorption / drug effects
Amlodipine / adverse effects,  pharmacokinetics*
Analysis of Variance
Calcium Channel Blockers / adverse effects,  pharmacokinetics*
Charcoal / administration & dosage*
Intestinal Absorption*
Overdose / prevention & control
Reg. No./Substance:
0/Calcium Channel Blockers; 16291-96-6/Charcoal; 88150-42-9/Amlodipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy...
Next Document:  Meloxicam pharmacokinetics in renal impairment.